Efficacy and Safety of Telbivudine Compared to Entecavir Among HBeAg+ Chronic Hepatitis B Patients: a Meta-Analysis Study

Authors Information
Article Notes and Dates
To Cite : Liang J, Jiang M J, Deng X, Xiao Zhou X. Efficacy and Safety of Telbivudine Compared to Entecavir Among HBeAg+ Chronic Hepatitis B Patients: a Meta-Analysis Study, Hepat Mon. 2013 ;13(6):e7862. doi: 10.5812/hepatmon.7862.
Copyright: Copyright © 2013, Hepatitis Monthly. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited..
Abstract
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
Acknowledgements
Footnotes
References
  • 1. Lok AS, McMahon BJ. Chronic hepatitis B. Hepatology. 2007; 45(2): 507-39[DOI][PubMed]
  • 2. Bosch FX, Ribes J, Cleries R, Diaz M. Epidemiology of hepatocellular carcinoma. Clin Liver Dis. 2005; 9(2): 191-211[DOI][PubMed]
  • 3. Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment, and current and emerging prevention and control measures. J Viral Hepat. 2004; 11(2): 97-107[PubMed]
  • 4. Sorrell MF, Belongia EA, Costa J, Gareen IF, Grem JL, Inadomi JM, et al. National Institutes of Health consensus development conference statement: management of hepatitis B. Hepatology. 2009; 49(5 Suppl)[DOI][PubMed]
  • 5. Lee C, Gong Y, Brok J, Boxall EH, Gluud C. Hepatitis B immunisation for newborn infants of hepatitis B surface antigen-positive mothers. Cochrane Database Syst Rev. 2006; (2)[DOI][PubMed]
  • 6. EASL Clinical Practice Guidelines: management of chronic hepatitis B. J Hepatol. 2009; 50(2): 227-42[DOI][PubMed]
  • 7. Dienstag JL, Schiff ER, Wright TL, Perrillo RP, Hann HW, Goodman Z, et al. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med. 1999; 341(17): 1256-63[DOI][PubMed]
  • 8. Gramenzi A, Loggi E, Micco L, Cursaro C, Fiorino S, Galli S, et al. Serum hepatitis B surface antigen monitoring in long-term lamivudine-treated hepatitis B virus patients. J Viral Hepat. 2011; 18(10)-74[DOI][PubMed]
  • 9. Perrillo RP, Hann HW, Schiff E, Mutimer D, Willems B, Leung N, et al. Extended treatment with lamivudine and adefovir dipivoxil in chronic hepatitis B patients with lamivudine resistance. Hepatol Int. 2011; 5(2): 654-63[DOI][PubMed]
  • 10. Marcellin P, Chang TT, Lim SG, Tong MJ, Sievert W, Shiffman ML, et al. Adefovir dipivoxil for the treatment of hepatitis B e antigen-positive chronic hepatitis B. N Engl J Med. 2003; 348(9): 808-16[DOI][PubMed]
  • 11. Dienstag J, Easley C, Kirkpatrick P. Telbivudine. Nat Rev Drug Discov. 2007; 6(4): 267-8[DOI][PubMed]
  • 12. Chan HL, Heathcote EJ, Marcellin P, Lai CL, Cho M, Moon YM, et al. Treatment of hepatitis B e antigen positive chronic hepatitis with telbivudine or adefovir: a randomized trial. Ann Intern Med. 2007; 147(11): 745-54[PubMed]
  • 13. Gane EJ, Wang Y, Liaw YF, Hou J, Thongsawat S, Wan M, et al. Efficacy and safety of prolonged 3-year telbivudine treatment in patients with chronic hepatitis B. Liver Int. 2011; 31(5): 676-84[DOI][PubMed]
  • 14. Hann HW. Telbivudine: an effective anti-HBV drug for chronic hepatitis B patients with early on-treatment responses. Expert Opin Pharmacother. 2010; 11(13): 2243-9[DOI][PubMed]
  • 15. Hou J, Yin YK, Xu D, Tan D, Niu J, Zhou X, et al. Telbivudine versus lamivudine in Chinese patients with chronic hepatitis B: Results at 1 year of a randomized, double-blind trial. Hepatology. 2008; 47(2): 447-54[DOI][PubMed]
  • 16. Lv GC, Ma WJ, Ying LJ, Jin X, Zheng L, Yang YD. Efficacy of telbivudine in HBeAg-positive chronic hepatitis B patients with high baseline ALT levels. World J Gastroenterol. 2010; 16(32): 4095-9[PubMed]
  • 17. FDA notifications. Entecavir is approved for chronic hepatitis B infection in adults. AIDS Alert. 2005; 20(7): 83-4[PubMed]
  • 18. Keeffe EB. Treatment of chronic hepatitis B with entecavir: High potency and absent viral resistance with 1 year of therapy. Evidence-Based Gastroenterol. 2006; 3(7): 79-80
  • 19. Gonzalez SA, Keeffe EB. Entecavir for the long-term treatment of chronic hepatitis B. Expert Rev Anti Infect Ther. 2009; 7(9): 1053-62[DOI][PubMed]
  • 20. Osborn M. Safety and efficacy of entecavir for the treatment of chronic hepatitis B. Infect Drug Resist. 2011; 4: 55-64[DOI][PubMed]
  • 21. Tenney DJ, Rose RE, Baldick CJ, Pokornowski KA, Eggers BJ, Fang J, et al. Long-term monitoring shows hepatitis B virus resistance to entecavir in nucleoside-naive patients is rare through 5 years of therapy. Hepatology. 2009; 49(5): 1503-14[DOI][PubMed]
  • 22. Zhang X, Lin SM, Ye F, Chen TY, Liu M, Chen YR, et al. An early decrease in serum HBeAg titre is a strong predictor of virological response to entecavir in HBeAg-positive patients. J Viral Hepat. 2011; 18(7)-90[DOI][PubMed]
  • 23. Chang TT, Gish RG, de Man R, Gadano A, Sollano J, Chao YC, et al. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B. N Engl J Med. 2006; 354(10): 1001-10[DOI][PubMed]
  • 24. Lai CL, Gane E, Chao-Wei H, Thongsawat S, Wang Y, Chen Y. Two-year results from the GLOBE trial in patients with hepatitis B: greater clinical and antiviral efficacy for telbivudine (LdT) vs. lamivudine. Hepatology. 2006; 44
  • 25. Zhu FY. Twenty-four weeks results of entecavir versus telbivudine treatments in patients with HBeAg-positive chronic hepatitis B. Clin J Med Offic. 2011; 1(39)
  • 26. Shi KQ, Zhang DZ, Guo SH, He H, Wang ZY, Shi XF, et al. [Short-term results of telbivudine versus entecavir treatments in HBeAg-positive chronic hepatitis B patients in China]. Zhonghua Gan Zang Bing Za Zhi. 2008; 16(9): 641-5[PubMed]
  • 27. Suh DJ, Um SH, Herrmann E, Kim JH, Lee YS, Lee HJ, et al. Early viral kinetics of telbivudine and entecavir: results of a 12-week randomized exploratory study with patients with HBeAg-positive chronic hepatitis B. Antimicrob Agents Chemother. 2010; 54(3): 1242-7[DOI][PubMed]
  • 28. Zheng MH, Shi KQ, Dai ZJ, Ye C, Chen YP. A 24-week, parallel-group, open-label, randomized clinical trial comparing the early antiviral efficacy of telbivudine and entecavir in the treatment of hepatitis B e antigen-positive chronic hepatitis B virus infection in adult Chinese patients. Clin Ther. 2010; 32(4): 649-58[DOI][PubMed]
  • 29. Huang J, Chen XP, Chen XF, Chen WL, Chen R, Ma XJ, et al. [Study on the efficacy and HBeAg seroconversion related factors of telbivudine and entecavir therapy in HBeAg positive chronic hepatitis B patients]. Zhonghua Gan Zang Bing Za Zhi. 2011; 19(3): 178-81[DOI][PubMed]
  • 30. Xu HX, Yu YX, Zhang MX, Wu YP, Liu XX, Chen Y. Application of telbivudine and entecavir in the treatment of patients with HBeAg-positive chronic hepatitis B. J Clin Hepatol. 2011; 4(14): 265-7
  • 31. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.4.
  • 32. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials. 1986; 7(3): 177-88[PubMed]
  • 33. Mantel N, Haenszel W. Statistical aspects of the analysis of data from retrospective studies of disease. J Natl Cancer Inst. 1959; 22(4): 719-48[PubMed]
  • 34. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics. 1994; 50(4): 1088-101[PubMed]
  • 35. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997; 315(7109): 629-34[PubMed]
  • 36. Easterbrook PJ, Berlin JA, Gopalan R, Matthews DR. Publication bias in clinical research. Lancet. 1991; 337(8746): 867-72[PubMed]
  • 37. Simes RJ. Publication bias: the case for an international registry of clinical trials. J Clin Oncol. 1986; 4(10): 1529-41[PubMed]
  • 38. Sterling TD, Rosenbaum WL, Weinkam JJ. Publication decisions revisited: The effect of the outcome of statistical tests on the decision to publish and vice versa. Am Stat. 1995; 49(1): 108-12
  • 39. Matthews SJ. Entecavir for the treatment of chronic hepatitis B virus infection. Clin Ther. 2006; 28(2): 184-203[DOI][PubMed]
  • 40. Almeida AM, Ribeiro AQ, Padua CA, Brandao CM, Andrade EI, Cherchiglia ML, et al. [The efficacy of adefovir dipivoxil, entecavir and telbivudine for chronic hepatitis B treatment: a systematic review]. Rev Soc Bras Med Trop. 2010; 43(4): 440-51[PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:

Author(s):

Article(s):

Create Citiaion Alert via Google Reader

Cited By:

Hepatitis Monthly accepts terms & conditions of:

International Committee of Medical Journal Editors (ICMJE) Citedby Linking DOI enabled Crossref iThenticate COPE Cross Check